Twenty-eight independently derived monoclonal antibodies (MAb) directed against Escherichia coli J5 endotoxin were produced and characterized. Each MAb exhibited a specific titer by both radioimmunoassay and passive hemagglutination assay. Most of the MAb were of the immunoglobulin G isotype; however, several immunoglobulin M antibodies and one immunoglobulin A antibody were produced. When characterized for their capacity to cross-react with purified endotoxin preparations from several gram-negative bacteria, 22 MAb exhibited no cross-reactivity; 6 demonstrated a limited capacity to cross-react with other endotoxin preparations. When characterized for their capacity to react with the intact organism instead of the purified endotoxin the pattern of cross-reactivity was quite different. Most of the MAb were able to react with Salmonella minnesota Re595. Eighteen were able to react with E. coli O111:B4 (the parent strain of E. coli J5), 13 MAb reacted weakly with Pseudomonas aeruginosa, and 3 reacted weakly with Klebsiella pneumonia. The data imply that MAb generated against E. coli J5 endotoxin demonstrate greater cross-reactivity when assayed against the whole bacterium than when assayed against the corresponding purified endotoxin. We were unable to demonstrate that any of the 28 MAb could passively protect mice against lethal endotoxin challenge.
Gram-negative bacteria have become the leading agents in fatal bacterial infections in hospitals. The mortality rate can be as high as 30 to 40% (9, 20, 29) . Individuals most often affected are patients whose immune system is suppressed, such as cancer patients receiving chemotherapy or radiation therapy, organ transplant patients receiving immunosuppressive drugs, and burn patients. Antibiotic therapy is relatively ineffective because of the ability of these organisms to develop resistance to the antibiotics and may worsen the condition by contributing to the release of endotoxin into the blood stream. It is for these reasons that passive immunization with antisera, or perhaps monoclonal antibodies (MAb), is being viewed as an attractive alternative.
The approach to the development of an antiserum is based on the requirement that it be protective against a broad spectrum of gram-negative organisms. Antibodies to gramnegative bacteria are directed primarily against the lipopolysaccharide (LPS), or outermost portion, of the cell wall. LPS is composed of three major parts; the 0 polysaccharide, the core region, and lipid A. Antisera to a wild-type organism primarily contains O-polysaccharide antibodies. Because the structure of the 0 polysaccharide differs widely from strain to strain, an antiserum to this portion of the molecule is usually protective against the biological effects of the immunizing strain but it is not protective against a wide variety of gram-negative bacteria (11) . There is much less strain variation in the core region of LPS and even less in the lipid A portion of the molecule. Bacterial mutants have been derived which lack the 0 polysaccharide and expose various portions of the core region and lipid A. The two mutants most commonly used for producing antibodies to core antigens are Escherichia coli J5 (8) and Salmonella minnesota Re595 (14) .
Over the last 15 years, investigators in several laboratories have reported that antisera to these mutant strains are * Corresponding author.
effective in the prctection of animals against a wide variety of experimentally induced bacteremias (2, 3, 5, 7, 16, 17, 27, 28) . Furthermore, Ziegler et al. (29) recently published the results of a 7-year clinical study which demonstrated that human antisera, prepared by vaccinating healthy men with E. coli J5, could protect bacteremic patients from death when compared with preimmune serum. Our interest in this area has centered around the possibility that a MAb directed against the common regions of LPS molecules could be effective in the protection against gramnegative sepsis. A library of murine MAb directed against E. coli J5 have been produced and characterized for their cross-reactive and cross-protective capacities.
MATERIALS AND METHODS
Endotoxins. Purified endotoxins were obtained from List Biological Laboratories (Campbell, Calif.) and contain <1% contaminating nucleic acids and proteins. According to the supplier, the endotoxins were prepared according to modifications of published methods (11, 19, 27, 30 Cell lines. Myelomas and hybridomas were maintained in Corning tissue culture flasks in Dulbecco modified Eagle medium (GIBCO Laboratories, Grand Island, N.Y.) containing 10 to 15% fetal bovine serum (Hyclone, Logan, Utah), 1% nonessential amino acids (GIBCO), and 50 ,ug of gentamicin (GIBCO) per ml. Cell cultures were grown at 37°C in a humidified incubator containing 7.5% CO2 in air.
Immunizations. Inbred 8-to 10-week-old female BALB/c mice (Jackson Laboratories, Bar Harbor, Maine) were immunized by one of two immunization schedules. Mice were immunized intraperitoneally with 0.25 ml of a heat-killed E. coli J5 suspension (see above) in complete Freund adjuvant on day 0 and boosted with the same dose in incomplete Freund adjuvant on days 14 and 21. Alternatively, mice were immunized subcutaneously with 0.25 ml of a heat-killed E. coli J5 suspension on days 0, 2, and 21. Sera designated immune mouse sera were collected 1 week after the final boost in each case and titered by a direct binding radioimmunoassay (RIA). Sera designated normal mouse sera were collected from unimmunized mice and used as a negative control.
New Zealand White rabbits (2 to 3 kg) were bled 1 week prior to immunization to obtain preimmune serum. On day 0, rabbits were immunized (intradermally at 5 to 10 sites on the back) with 1.0 ml of a heat-killed E. coli J5 suspension in complete Freund adjuvant. Rabbits were boosted 1 month later with E. coli J5 in incomplete Freund adjuvant, using the same dose and regimen.
Fusion and generation of MAb. Mice were boosted intravenously 3 days prior to hybridization with 0.1 ml of a heat-killed suspension of E. coli J5 (see above). Spleen cells were fused with Sp2/0 murine myeloma cells (Human Genetic Mutant Cell Repository, Camden, N.J.) according to published methods (24) . Positive cells were cloned at least once by limiting dilution or in soft agar. Hybridoma ascites were obtained by injecting pristane (2,6,10,14-tetramethylpentadecane)-primed mice with 107 cells and aseptically removing the ascites fluid 7 to 10 days later.
RIA. A direct binding RIA was used for the initial screening and characterization of anti-endotoxin antibody. Briefly, 96-well microtiter plates (Dynatech Laboratories, Inc., Alexandria, Va.) were coated with antigen (endotoxin at 1 ,ug/ml or a suspension of the heat-killed organism; see above) and allowed to stand overnight at 4°C. The plates were washed and blocked with 10% agamma horse serum (GIBCO) followed by the addition of 100 RI of tissue culture supernatant or ascites fluid containing MAb. The plates were labeled with radioiodinated goat anti-mouse immunoglobulin (approximately 50,000 cpm/well). Samples were always assayed in duplicate. Background counts were determined with ascites fluid containing an unrelated MAb directed against hepatitis B surface antigen. RIA titers were determined with 10-fold dilutions of ascites fluid and were recorded as the dilution at which the counts per minute bound were twice the background counts bound. Competition RIA studies were performed by preincubating the MAb with either the desired endotoxin or heat-killed organisms at various concentrations for 4 h at 37°C before adding the mixture to an antigen-coated plate.
Passive hemagglutination. Anti-endotoxin activity of the MAb was also determined by passive hemagglutination, using sheep erythrocytes coated with E. coli J5 endotoxin (6) . Agglutination was facilitated with rabbit anti-mouse antisera which had been previo4sly absorbed with sheep erythrocytes. Hemagglutination titers were determined with serial twofold dilutions and werie recorded as the reciprocal of the endpoint dilution.
Isotyping Passive protection by heat-inactivated rabbit serum or heat-inactivated ascites fluid containing MAb was measured in the above assays. The antibody was injected either intraperitoneally or intravenously 1 h before challenge with endotoxin. RESULTS Characterization of MAb to E. coli J5 endotoxin. Twentyeight stable independently derived hybridomas secreting MAb to E. coli J5 endotoxin were derived from two fusions.
The animals used for the fusions were immunized by one of two protocols described in Materials and Methods. Ascites fluid induced by each of the cloned hybridomas was used as a source of MAb in the studies reported here. Most of the hybridomas produced IgG antibodies; however, we obtained several IgM clones and one IgA clone (Table 1) . We were unable to isotype two of our MAb with the reagents available; they may be IgE. The MAb titer in ascites fluid was assessed by both RIA and passive hemagglutination, using purified E. coli J5 endotoxin as test antigen. Each of the ascites exhibited a specific titer by both RIA and passive hemagglutination: however, the titers do not always correlate with one another. This may be due to the way in which the antibodies agglutinate and precipitate antigen or the way in which the antigen is presented in the two assays. The concentration of each MAb is also presented in Table 1. VOL. 52, 1986 on November 6, 2017 by guest http://iai.asm.org/ Table 2 . Immune mouse sera generated by immunizing mice with heat-killed E. coli J5 bacteria showed antibody activity to E. coli J5 endotoxin and E. coli 0111:B4 endotoxin (the parent strain of E. coli J5) but exhibited little cross-reactivity with other purified endotoxin preparations. Normal mouse serum exhibited little reactivity with any of the purified endotoxin preparations. MAb 1883.4 also showed specific binding to purified lipid A in the RIA (data not shown), but the other MAb bound to the J5 LPS but not lipid A.
To confirm our direct binding RIA results, we assessed the cross-reactive binding capacity of several MAb by a competition RIA in which purified endotoxin at various concentrations was preincubated with MAb before adding the mixture to an E. coli J5 endotoxin-coated RIA plate. The results of a competition binding study, using two different MAb, are presented in Fig. 1 . Figure 1A represents those MAb which exhibit no cross-reactivity and Fig. 1B represents those MAb which are cross-reactive. In all assays the homologous endotoxin was an effective inhibitor. A correlation of the direct binding RIA data and the competition RIA data is presented in Table 3 . With a few exceptions (most notably the reactivity of clones 1733.6 and 1883.4 with E. coli O111:B4 endotoxin), there was good correlation between the two assays. One possible explanation for the binding pattern elicited by MAb 1733.6 and 1883.4 is that the physical nature of drying LPS onto plates exposes determinants not normally exposed when LPS is in suspension.
When cross-reactivity was assessed in a direct binding assay with the whole bacteria instead of the purified endotoxin, the pattern of reactivity was quite different ( Table 4) . As expected, all of the MAb reacted with E. coli J5. Most of the MAb reacted with S. minnesota Re595, whereas none exhibited a high binding activity to the purified endotoxin from S. minnesota Re595. Eighteen MAb reacted with E. coli O111:B4, yet only two of these (1733.6 and 1883.4) were able to react with the corresponding purified endotoxin. Thirteen of the MAb demonstrated a low binding activity to P. aeruginosa and three demonstrated low binding to K. pneumonia. When the cross-reactivity was assessed by a competition RIA, using a whole bacterial suspension instead of purified endotoxin, good correlation between the direct binding assay and the competition assay was found. Figure 2 represents a typical dose response curve and Table 5 shows the correlation.
Passive protection studies. The protective potential of our MAb in a lethal endotoxin challenge assay was assessed. Since the LD50 of normal mice to E. coli J5 endotoxin is approximately 150 ,ug, it was necessary to sensitize the mice to demonstrate passive protection with immune rabbit antisera. Administration of actinomycin D at the time of LPS challenge lowered the LD50 to 2 ng. When 0.2 ml of immune rabbit serum was given 1 to 2 h before challenge, there was a sixfold increase in LD50, with no significant protection demonstrated with preimmune sera. All MAb were assayed with these actinomycin D-sensitized animals. However, none of the MAb protected mice in this assay system. There has been an increasing interest in the potential protective activity of antibodies to gram-negative organisms. Several early studies indicated that antisera against smooth bacteria can neutralize the toxicity of homologous endotoxin (1, 11, 22, 26) but not heterologous endotoxin (11) . Because of the vast heterogeneity found among strains of gramnegative organisms, the only therapeutically useful antibodies would be ones that protected against a broad spectrum of gram-negative organisms. During the last 15 years, therefore, an emphasis has been placed on characterizing antisera to rough mutants of gram-negative bacteria which lack the heterogeneous 0 polysaccharide and expose the more highly conserved core and lipid A regions of the LPS molecule. The reports of cross-reactive and protective antisera to rough mutants are conflicting, however. Several laboratories have reported that antisera to these rough mutants are effective in the protection of animals (2, 3, 5, 7, 16, 17, 27, 28) and humans (29) against a wide variety of experimentally induced bacteremias. Other reports indicate that such antisera is not protective (11, 18, 21) . Greisman et al. (11) have suggested that something other than antibody in serum might be protective because, in some cases, preimmune rabbit serum is as effective as hyperimmune sera in the protection of mice against infection. Now, with the development of hybridoma technology, it should be possible to determine if antibodies are protective against gram-negative infection. In fact, MAb directed against gram-negative organisms have been reported (6, 13, 19) . Two of the reports characterized MAb directed against smooth bacteria with an intact 0 polysaccharide portion of LPS and protection was observed when mice were challenged with the homologous strain (6, 13). Mutharia et al. (19) recently reported the production of cross-reactive MAb to E. coli J5 endotoxin. Protection studies were not described in the report.
In the present study, 28 murine MAb directed against E. coli J5 endotoxin were characterized for their ability to cross-react with other gram-negative organisms. When the MAb were assayed in a direct binding RIA with purified endotoxin as the coating antigen, 22 were unable to react with any of the endotoxin preparations tested except E. coli J5. Six MAb demonstrated some capacity to cross-react with other endotoxin preparations, but the cross-reactivity was limited primarily to other types of E. coli and some strains of Salmonella spp. The direct binding RIA pattern was confirmed by a competitive binding study. When the MAb were characterized for their ability to react with the heat-killed whole bacterium, however, many more of the MAb demonstrated cross-reactivity. Most of the MAb reacted with S. minnesota Re595 which lacks both the 0 polysaccharide and the inner core region of the LPS molecule. Furthermore, 18 MAb reacted with E. coli O111:B4, the parent strain of E. coli J5. Thirteen MAb were able to react weakly with P. aeruginosa and there was much less binding activity to K. pneumoniae. The implication of this study is that MAb generated against E. coli J5 endotoxin demonstrate greater cross-reactivity when assayed against the whole bacterium than when assayed against the corresponding purified endotoxin preparation. One explanation for this is that the cross-reactive antigenic determinant(s) on the LPS molecule is somehow modified during the purification process but is present and accessible on the intact bacterium. Another possibility is that there are common antigens on the surface of gram-negative bacteria which are not part of the LPS molecule. A third possibility is that whole bacterial cells synthesize incomplete LPS moities in small amounts which could account for the cross-reactivity observed. In addition, it is known that small amounts of R core are synthesized in the S. minnesota Re595 mutant.
We assessed the protective potential of the MAb in a lethal LPS challenge assay. Because mice are relatively resistant to challenge with LPS, an effective method of sensitizing the mice was established. We found that it was necessary to lower the LD50 to approximately 2 ng of E. coli J5 endotoxin before passive protection with rabbit antisera could be demonstrated. All MAb were tested in this assay with the highly sensitized animals and no significant protection was ever observed. We also attempted several lethal infection assays with E. coli J5 but were unsuccessful in demonstrating passive protection. E. coli J5 is a relatively avirulent organism in mice (LD50 = 109 organisms); therefore, it is difficult to assess the protective ability of the MAb in this assay due to the magnitude of the bacterial challenge.
In conclusion, a library of MAb directed against E. coli J5 LPS have been produced. Most of these antibodies exhibited some cross-reactive binding potential when assayed against the whole bacterium but were not cross-reactive when assayed against the purified endotoxin. We were unable to demonstrate that these MAb were protective in mice. However, protection is difficult to assess because of the high natural resistance of these animals to gram-negative organisms.
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